MannKind CFO says has 'no news' to account for today's stock movement MannKind (MNKD) CFO Matthew Pfeffer cites speculation that the company planned to pull out of attending Wells Fargo's conference, which was unfounded. Pfeffer also says some pointed to erroneous reporting of a link between MannKind and Zyprexa, an Eli Lilly (LLY) drug with which MannKind has "no connection," though Pfeffer added that he does not believe confusion about news related to Zyprexa was a cause for the stock move. The comments were made by Pfeffer while speaking at a Wells Fargo healthcare conference.
MannKind triples production capacity for Afrezza MannKind announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.